<p>Raju Prasad, Chief Financial Officer of CRISPR Therapeutics AG, reported a disposal of common shares of the company, according to a recent regulatory filing. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-331162), on December 23, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

CRSP

<p>Raju Prasad, CFO of CRISPR Therapeutics AG, has reported the sale of common shares of the company, as per a regulatory filing. The filing is accessible via EDGAR, the SEC's system. This news brief is AI-generated by Public Technologies and is not financial advice.</p>

CRISPR Therapeutics CFO Prasad Raju Reports Sale of Common Shares